Jamie Hirata

Jamie Hirata

Company: Genentech

Job title: Global Development Leader


Polatuzumab Vedotin: Late Stage Clinical Development to Approval 9:30 am

Providing an overview of the late stage clinical development of polatuzumab vedotin Discussing rational combination strategy in R/R DLBCL leading to approval of polatuzumab vedotin + BR Sharing the rational combination strategy in 1L DLBCL leading to positive results of the Phase III POLARIX with polatuzumab vedotin + R-CHPRead more

day: day 2- am

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.